Sex, steroids and anabolic androgens in athletics
Androgens and doping tests: genetic variation and pit-falls
Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review
Intracerebroventricular opioids for intractable pain
Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol?
Bioequivalence of two omega-3 fatty acid ethyl ester formulations: a case of clinical pharmacology of dietary supplements
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs
Pharmacokinetics of linagliptin in subjects with hepatic impairment
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABAA receptor modulator – an in vitro and in vivo comparison
Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data
Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices
Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants
Implementing a statin switching programme in primary care: patients' views and experiences
Correlation of paired toxic plasma and saliva paracetamol concentrations following deliberate self-poisoning with paracetamol
Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation
The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings
Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study
Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure
Trends of reporting of ‘serious’ vs . ‘non-serious’ adverse drug reactions over time: a study in the French PharmacoVigilance Database
A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19 * 17/ * 17 patient comedicated with carbamazepine
Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from randomized controlled trials
Authors' response to Hermann et al . Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from RCTs
Translation Section
Expression of concern